Jaypirca 100 mg film-coated tablets

DRUG4 trials

Sponsors

Genmab A/S, Fundacion Geltamo, University Of Cologne, BeOne Medicines AG

Conditions

Adult patients with indolent MCL who have not previously received treatment (naïve patients).Chronic Lymphocytic LeukemiaChronic lymphocytic leukemia (CLL)Small lymphocytic lymphoma (SLL)irrespective of risk factors and disease stagepreviously untreated RT

Phase 1

A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

RecruitingCTIS2023-504828-25-00

Genmab A/SChronic Lymphocytic Leukemia

Start: 2020-11-16Target: 125Updated: 2025-11-20

Phase 2

International multicentric phase II trial to evaluate the efficacy and safety of pirtobrutinib in combination with rituximab in patients with indolent clinical forms of Mantle Cell Lymphoma

RecruitingCTIS2024-511983-97-00

Fundacion GeltamoAdult patients with indolent MCL who have not previously received treatment (naïve patients).

Start: 2025-09-29Target: 50Updated: 2025-06-24

Phase 3

A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

RecruitingCTIS2025-522860-34-00

BeOne Medicines AGChronic lymphocytic leukemia (CLL), Small lymphocytic lymphoma (SLL)

Start: 2025-12-16Target: 196Updated: 2026-01-21

A prospective, open-label, randomized, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R-(mini)-CHOP for treatment of patients with Richter Transformation - CLLRT2

Not yet recruitingCTIS2024-513445-37-00

University Of Cologneirrespective of risk factors and disease stage, previously untreated RT

Target: 41Updated: 2026-03-18